Drugs / Recombinant new coronavirus vaccine (CHO cells)
Recombinant new coronavirus vaccine (CHO cells)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05091411 | Sep → Nov 2021 | COVID-19 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant new coronavirus vaccine (CHO cells) | “Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).” NCT05091411 ↗ |
| Modality | Vaccine | “Recombinant new coronavirus vaccine (CHO cells)” NCT05091411 ↗ |
| Route | Intramuscular | “Intramuscular injection of deltoid muscle of upper arm” NCT05091411 ↗ |